ESR1 and breast cancer: Preclinical data suggest that activation of the PI3K pathway, via mutation of PIK3CA, loss of phosphatase and tensin homolog (PTEN) expression, or HER2 overexpression, may promote resistance to antiestrogen therapy and hormonal independence in estrogen receptor (ER)-positive models of breast cancer [13–15].